Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.